HIV/STIs
> Relationship of Hormonal Contraceptive Use to HIV Transmission: Frequently Asked Questions
In May, 2005 Gynuity held a meeting on the relationship of hormonal contraceptive use to HIV transmission and disease progression. The meeting examined the most up-to-date evidence on the topic, needs and strategies for future research, and what actions family planning and HIV prevention programs should currently be taking in response to what is known. Information on this topic is available below.
| > List of Questions and Answers on this topic |
|
| > Path's issue of Outlook newsletter on hormonal contraception and HIV |
|
| > Issue brief on hormonal contraception and HIV |
|
Back to top
|
Incomplete Abortion (PAC)
|
 |
> Instructions for Use of Misoprostol for Incomplete Abortion
Gynuity Health Projects and Reproductive Health Technologies Project convened an expert meeting looking at the use of misoprostol for incomplete abortion and miscarriage. Professionals with epidemiological, clinical and programmatic expertise reached consensus on the appropriate use of misoprostol based on the best current information. The results can be found in a brochure called “Instructions for Use." The information in this document may serve as a basis for the development of clinical practice guidelines and patient and provider education materials. This brochure will be periodically reviewed and updated with new information and research developments. |
Download Instructions for Use: Misoprostol for Treatment of Incomplete Abortion and Miscarriage
| > |
List of meeting participants |
|
| > |
Reference list |
|
| > |
Annotated bibliography
(available as an insert in the PAC Consortium newsletter below) |
English and Spanish versions of both documents are also available in a brochure format. For complimentary orders of up to 100 brochures, contact us at pubinfo@gynuity.org.
> Download the PAC Consortium's newsletter on this topic.
|
Back to top
Medical Abortion
 |
> Providing Medical Abortion in Developing Countries: An Introductory Guidebook
Gynuity produced a tool for providers and policy makers who are interested in introduction of medical methods for safe termination of early pregnancy. Providing Medical Abortion in Developing Countries: An Introductory Guidebook is now available in Arabic, English, French, Portuguese, Romanian, Russian, Spanish, and Vietnamese in PDF format. Contact pubinfo@gynuity.org to obtain print copies of the guidebook in English, Russian and Spanish. |
|
> Instructions for Use of Misoprostol for Early Abortion
Gynuity Health Projects and Reproductive Health Technologies Project convened an expert meeting looking at the use of misoprostol for abortion induction. Professionals with epidemiological, clinical and programmatic expertise reached consensus on the appropriate use of misoprostol based on the best current information. The results can be found in a brochure called “Instructions for Use." The information in this document may serve as a basis for the development of clinical practice guidelines and patient and provider education materials. The brochure will be periodically reviewed and updated with new information and research developments. |
|
Download Instructions for Use: Abortion Induction with Misoprostol in Pregnancies through 9 Weeks LMP
| > List of meeting participants |
|
| > Reference list |
|
| > Annotated bibliography |
|
|
|
> Fatal Infection and Mifepristone Medical Abortion: Frequently Asked Questions
Gynuity and colleagues compiled a series of Frequently Asked Questions (FAQs) and their answers aimed at giving medical abortion providers and women’s health advocates the language to discuss the occurrence of severe infections caused by Clostridium sordellii following mifepristone-misoprostol medical abortion so they are able to present the science in an informed and responsible manner.
> FAQs on Infection and Medical Abortion - Technical Version |
|
|
|
 |
|
|
|
|
> FAQs on Infection and Medical Abortion - Summary |
|
|
|
|
|
|
|
|
> PPFA's issue of Mife Matters on infection and medical abortion |
|
In May, 2006, the U.S. Department of Health and Human Services, the Centers for Disease Control and Prevention, the Food and Drug Administration and the National Institutes of Health convened a workshop in Atlanta, Georgia on clostridial disease. The goal of the public workshop was to identify research needs and priorities to enable rapid progress in understanding reports of morbidity and mortality associated with clostridial disease. The full meeting transcript can be obtained on the FDA's website.
Download a summary of the workshop outcomes here 
|
| |
> Medical Abortion in the U.S.: Mifepristone Fact Sheet
As part of our effort to defend mifepristone and medical abortion in the United States, Gynuity and Reproductive Health Technologies Project developed a fact sheet about mifepristone use in the U.S. to provide advocates and policy makers with concise information on regimens, safety and benefits.
> Mifepristone fact sheet |
|
|
| |
> Misoprostol and Teratogenicity: Reviewing the Evidence
The abortifacient properties of misoprostol are well known to medical professionals and often to the general public. In fact, women have chosen to self-administer misoprostol to terminate their pregnancies, particularly in settings where abortion services are not available. The medical community and women's health advocates have expressed concern that in those instances where the woman has a failed abortion and then continues the pregnancy to term, the exposure to misoprostol could potentially result in birth defects in the child. Indeed, several reports of birth anomalies have surfaced in the scientific literature, and subsequent studies have explored this question. Yet the true teratogenic potential of misoprostol has been obscured, perhaps overestimated, by the reasonable concern for the well being of the child.
Given this controversy in the field, a select number of experts from the fields of embryology, obstetrics and gynecology, epidemiology, teratology, physiology, and drug development gathered in May 2002 to discuss the possible teratogenic effects of misoprostol. The meeting report, Misoprostol and Teratogenicity: Reviewing the Evidence, compiles the relevant research on the putative teratogenicity of misoprostol as well as the expert conclusion determined during the meeting.
Download the meeting report in PDF format in the following languages:
|
| |
> Choices for Medical Abortion Introduction in Brazil, Colombia, Mexico and Peru
This working paper summarizes information about medical abortion regimens, describes the context and availability of medical abortion drugs in four Latin American countries, and reviews specific issues relevant to the introduction of medcial abortion regimens.
Download the working paper in the following languages:
|
| |
|
| |
|
 |
> Instructions for Use of Misoprostol for Prevention of Postpartum Hemorrhage
The third in a series, this Instructions for Use (IFU) brochure on the use of misoprostol for prevention of postpartum hemorrhage was drafted based on current available information. In June 2007, Gynuity invited professionals with epidemiological, clinical and programmatic expertise on PPH prevention and misoprostol to review this document. The aim of this collaborative review was to reach consensus on clinical practice guidelines and make available evidence-based information on appropriate use of misoprostol for this indication. This brochure will soon be available in multiple languages and periodically reviewed and updated as new information and research developments become available. |
Download Instructions for Use of Misoprostol for Prevention of Postpartum Hemorrhage |
| |
|
|
 |
 |
|
| |
> Reference list |
|
|
|
|
| |
 |
Postpartum Hemorrhage: A Challenge for Safe Motherhood provides an overview of one of the major causes of maternal death and disability in developing countries: severe bleeding following childbirth. The fact sheet defines postpartum hemorrhage and describes its prevalence worldwide; outlines why women in developing countries are at greater risk of dying from severe bleeding; and proposes specific actions that policy makers and other stakeholders can undertake to address the problem. |
|
Postpartum Hemorrhage: Responding to the Challenge outlines the potential role of a widely available drug (misoprostol) in reducing deaths from postpartum hemorrhage, and describes an iinitiative being undertaken to evaluate misoprostol as an alternative therapy for postpartum hemorrhage prevention and treatment. The document lists the potential advantages of misoprostol (as compared to standard treatments) in resource-constrained settings, describes the rationale, objectives, and protocols related to the research efforts, and outlines a set of related project activities to shape policy and share information in support of misoprostol for postpartum hemorrhage.
Both documents are forthcoming in Arabic in PDF format. To obtain print copies of either document in English, French or Spanish, please contact Family Care International at fcipubs@fcimail.org or Gynuity at pubinfo@gynuity.org.
For information about our postpartum hemorrhage trials, download the following summaries.
> Misoprostol for treatment of PPH |
|
> Misoprostol for adjunct treatment of PPH - WHO collaboration |
|
> Pakistan PPH treatment study |
|
> Pakistan PPH prevention study |
|
> Summary on measured blood loss for PPH
> Summary on fever in PPH treatment
Back to top
|
